MARVELD3

Summary

MARVELD3 (MARVEL domain containing 3, HGNC:30525) is a protein-coding gene on chromosome 16q22.2, encoding MARVEL domain-containing protein 3 (Q96A59). As a component of tight junctions, plays a role in paracellular ion conductivity.

Enables mitogen-activated protein kinase kinase kinase binding activity. Involved in bicellular tight junction assembly. Acts upstream of or within several processes, including negative regulation of JNK cascade; negative regulation of epithelial cell migration; and protein localization to cell junction. Located in bicellular tight junction and cytoplasmic vesicle.

Source: NCBI Gene 91862 — RefSeq curated summary.

At a glance

• GWAS associations: 9
• Clinical variants (ClinVar): 56 total
• MANE Select transcript: NM_052858

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30525
Approved symbol	MARVELD3
Name	MARVEL domain containing 3
Location	16q22.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000140832
Ensembl biotype	protein_coding
OMIM	614094
Entrez	91862

Gene structure

Transcript identifiers

Ensembl transcripts: 5 — 4 protein_coding, 1 protein_coding_CDS_not_defined

ENST00000268485, ENST00000299952, ENST00000561682, ENST00000565261, ENST00000567566

RefSeq mRNA: 3 — MANE Select: NM_052858 NM_001017967, NM_001271329, NM_052858

CCDS: CCDS10904, CCDS32478, CCDS59270

Canonical transcript exons

ENST00000268485 — 3 exons

Exon	Start	End
ENSE00001200668	71634193	71636465
ENSE00001843514	71626184	71626696
ENSE00003635682	71629367	71629494

Expression profiles

Bgee: expression breadth ubiquitous, 179 present calls, max score 94.94.

FANTOM5 (CAGE): breadth broad, TPM avg 3.7928 / max 103.5570, expressed in 482 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
154925	2.9475	461
154924	0.6167	330
154926	0.2286	152

Top tissues by expression

241 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
ileal mucosa	UBERON:0000331	94.94	gold quality
buccal mucosa cell	CL:0002336	94.86	gold quality
mucosa of transverse colon	UBERON:0004991	91.84	gold quality
pancreatic ductal cell	CL:0002079	91.66	silver quality
jejunal mucosa	UBERON:0000399	90.72	gold quality
duodenum	UBERON:0002114	88.52	gold quality
kidney epithelium	UBERON:0004819	88.15	silver quality
rectum	UBERON:0001052	86.78	gold quality
nasal cavity epithelium	UBERON:0005384	86.13	silver quality
colonic mucosa	UBERON:0000317	85.75	gold quality
body of pancreas	UBERON:0001150	84.50	gold quality
mucosa of sigmoid colon	UBERON:0004993	84.47	gold quality
pancreas	UBERON:0001264	83.29	gold quality
parotid gland	UBERON:0001831	82.46	silver quality
small intestine Peyer’s patch	UBERON:0003454	82.42	gold quality
transverse colon	UBERON:0001157	82.34	gold quality
small intestine	UBERON:0002108	82.25	gold quality
amniotic fluid	UBERON:0000173	81.27	gold quality
islet of Langerhans	UBERON:0000006	81.17	gold quality
metanephros cortex	UBERON:0010533	79.55	gold quality
endothelial cell	CL:0000115	79.45	silver quality
olfactory segment of nasal mucosa	UBERON:0005386	79.18	gold quality
saliva-secreting gland	UBERON:0001044	78.83	gold quality
adult mammalian kidney	UBERON:0000082	78.72	gold quality
minor salivary gland	UBERON:0001830	78.48	gold quality
jejunum	UBERON:0002115	78.22	gold quality
nasal cavity mucosa	UBERON:0001826	78.01	gold quality
esophagus squamous epithelium	UBERON:0006920	77.50	silver quality
kidney	UBERON:0002113	77.04	gold quality
mouth mucosa	UBERON:0003729	76.96	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.05
E-MTAB-6386	no	4.74

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

53 targeting MARVELD3, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-9983-3P	99.94	71.48	3631
HSA-MIR-4648	99.91	67.00	710
HSA-MIR-4302	99.89	67.94	1187
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-MIR-129-5P	99.88	70.26	3273
HSA-MIR-182-5P	99.87	74.03	2589
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-10393-5P	99.65	68.01	1368
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-1290	99.59	69.90	2079
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-5004-3P	99.54	68.27	1371
HSA-MIR-106A-3P	99.53	67.58	995
HSA-MIR-3182	99.40	68.15	2454
HSA-MIR-6839-3P	99.39	68.86	1301
HSA-MIR-3140-5P	99.39	69.04	1136
HSA-MIR-548B-3P	99.38	67.26	1000
HSA-MIR-3911	99.38	66.95	1087
HSA-MIR-377-3P	99.37	70.18	1905
HSA-MIR-155-5P	99.35	70.16	1509
HSA-MIR-4777-5P	99.33	67.53	1148

Literature-anchored findings (GeneRIF, showing 6)

• MarvelD3 co-localises with occludin at tight junctions in intestinal and corneal epithelial cells. (PMID:20028514)
• marvelD3, occludin, and tricellulin define the tight junction-associated MARVEL protein family (PMID:20164257)
• MarvelD3 is transcriptionally downregulated in Snail-induced epithelial-mesenchymal transition during the progression for the pancreatic cancer. (PMID:21763689)
• MarvelD3 couples tight junctions to the MEKK1-JNK pathway to regulate cell behavior and survival. (PMID:24567356)
• Role of tight junction-associated MARVEL protein marvelD3 in migration and epithelial-mesenchymal transition of hepatocellular carcinoma. (PMID:34338154)
• MARVELD3 inhibits the epithelial-mesenchymal transition and cell migration by suppressing the Wnt/beta-catenin signaling pathway in non-small cell lung cancer cells. (PMID:36924014)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	marveld3	ENSDARG00000099654
mus_musculus	Marveld3	ENSMUSG00000001672
rattus_norvegicus	Marveld3	ENSRNOG00000016291

Paralogs (2): PQBP1 (ENSG00000102103), CACTIN (ENSG00000105298)

Protein

Protein identifiers

MARVEL domain-containing protein 3 — Q96A59 (reviewed: Q96A59)

All UniProt accessions (2): Q96A59, J3KSM2

UniProt curated annotations — full annotation on UniProt →

Function. As a component of tight junctions, plays a role in paracellular ion conductivity.

Subcellular location. Membrane. Cell junction. Tight junction.

Isoforms (3)

UniProt ID	Names	Canonical?
Q96A59-1	1	yes
Q96A59-2	2
Q96A59-3	3

RefSeq proteins (3): NP_001017967, NP_001258258, NP_443090* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR008253	Marvel	Domain
IPR053077	MARVEL_domain_protein_3	Family

UniProt features (20 total): topological domain 5, transmembrane region 4, compositionally biased region 3, splice variant 3, chain 1, domain 1, region of interest 1, sequence variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96A59-F1	65.52	0.21

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 112 (showing top): GSE45365_CD8A_DC_VS_CD11B_DC_IFNAR_KO_MCMV_INFECTION_DN, GSE45365_NK_CELL_VS_CD8A_DC_MCMV_INFECTION_UP, GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_DN, GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_CELL_PROLIFERATION, chr16q22, GOZGIT_ESR1_TARGETS_DN, GOBP_APICAL_JUNCTION_ASSEMBLY, GOBP_REGULATION_OF_EPITHELIAL_CELL_MIGRATION, GOBP_NEGATIVE_REGULATION_OF_MAPK_CASCADE, GOBP_AMEBOIDAL_TYPE_CELL_MIGRATION, GOBP_NEGATIVE_REGULATION_OF_INTRACELLULAR_SIGNAL_TRANSDUCTION, GOBP_NEGATIVE_REGULATION_OF_MULTICELLULAR_ORGANISMAL_PROCESS, GOBP_CELL_JUNCTION_ORGANIZATION, GOBP_NEGATIVE_REGULATION_OF_EPITHELIAL_CELL_MIGRATION, GOBP_TISSUE_MIGRATION

GO Biological Process (7): response to osmotic stress (GO:0006970), negative regulation of epithelial cell migration (GO:0010633), cell-cell junction organization (GO:0045216), negative regulation of JNK cascade (GO:0046329), negative regulation of epithelial cell proliferation (GO:0050680), bicellular tight junction assembly (GO:0070830), protein localization to cell junction (GO:1902414)

GO Molecular Function (2): mitogen-activated protein kinase kinase kinase binding (GO:0031435), protein binding (GO:0005515)

GO Cellular Component (4): bicellular tight junction (GO:0005923), membrane (GO:0016020), cytoplasmic vesicle (GO:0031410), anchoring junction (GO:0070161)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
response to stress	1
response to abiotic stimulus	1
epithelial cell migration	1
regulation of epithelial cell migration	1
negative regulation of cell migration	1
negative regulation of multicellular organismal process	1
cell junction organization	1
JNK cascade	1
negative regulation of MAPK cascade	1
regulation of JNK cascade	1
negative regulation of cell population proliferation	1
epithelial cell proliferation	1
regulation of epithelial cell proliferation	1
apical junction assembly	1
tight junction assembly	1
intracellular protein localization	1
protein kinase binding	1
binding	1
apical junction complex	1
tight junction	1
cellular anatomical structure	1
cytoplasm	1
intracellular vesicle	1
cell junction	1

Protein interactions and networks

STRING

0 interactions, top by confidence (×1000):

IntAct

3 interactions, top by confidence:

A	B	Type	Score
SLCO1B1	CLGN	psi-mi:“MI:0914”(association)	0.350
SLCO1B3	SNAP23	psi-mi:“MI:0914”(association)	0.350

BioGRID (3): MARVELD3 (Affinity Capture-RNA), MARVELD3 (Affinity Capture-MS), MARVELD3 (Affinity Capture-MS)

ESM2 similar proteins: A4IIV4, A8MUP6, D3Z7H4, D3ZK93, O75204, P70259, P82352, Q08CE6, Q0IIE5, Q14714, Q2KHT4, Q2M2E3, Q2T9K0, Q3SZ72, Q3SZT1, Q3UUA0, Q497B3, Q498W5, Q49LS3, Q4V922, Q504G0, Q53RY4, Q5M962, Q5RCD5, Q5VW38, Q5XGU1, Q6AXT9, Q6AYL2, Q6P5F7, Q6PCP7, Q6UX68, Q6UXU4, Q7TQI0, Q80ZU9, Q8BGP5, Q8K177, Q8K451, Q8R1W2, Q8R2K4, Q8VHW3

Diamond homologs: Q96A59, Q9D956

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

56 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	46
Likely benign	3
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

491 predictions. Top by Δscore:

Variant	Effect	Δscore
16:71629491:AGAG:A	donor_loss	1.0000
16:71629493:AGGT:A	donor_loss	1.0000
16:71629494:GGTG:G	donor_loss	1.0000
16:71629495:GT:G	donor_loss	1.0000
16:71629496:T:G	donor_loss	1.0000
16:71626358:G:GT	donor_gain	0.9900
16:71626664:G:GT	donor_gain	0.9900
16:71626694:AAGG:A	donor_loss	0.9900
16:71626696:GGTGA:G	donor_loss	0.9900
16:71626697:G:C	donor_loss	0.9900
16:71626698:T:A	donor_loss	0.9900
16:71629361:TTATA:T	acceptor_loss	0.9900
16:71629362:TATA:T	acceptor_loss	0.9900
16:71629364:TAGT:T	acceptor_loss	0.9900
16:71629365:A:AG	acceptor_gain	0.9900
16:71629365:A:G	acceptor_loss	0.9900
16:71629365:AGT:A	acceptor_gain	0.9900
16:71629366:G:A	acceptor_loss	0.9900
16:71629366:G:GA	acceptor_gain	0.9900
16:71629366:GT:G	acceptor_gain	0.9900
16:71629366:GTG:G	acceptor_gain	0.9900
16:71629366:GTGA:G	acceptor_gain	0.9900
16:71629366:GTGAA:G	acceptor_gain	0.9900
16:71629492:GAG:G	donor_gain	0.9900
16:71629358:T:TA	acceptor_gain	0.9800
16:71626420:A:T	donor_gain	0.9700
16:71629360:GTTAT:G	acceptor_loss	0.9700
16:71629497:G:GT	donor_loss	0.9700
16:71626665:A:T	donor_gain	0.9600
16:71626668:G:GT	donor_gain	0.9600

AlphaMissense

2570 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:71634651:T:C	F352L	0.993
16:71634653:C:A	F352L	0.993
16:71634653:C:G	F352L	0.993
16:71634373:A:T	D259V	0.990
16:71634617:G:C	R340S	0.989
16:71634617:G:T	R340S	0.989
16:71634337:T:G	F247C	0.988
16:71634372:G:C	D259H	0.988
16:71634381:T:C	F262L	0.986
16:71634383:C:A	F262L	0.986
16:71634383:C:G	F262L	0.986
16:71634606:T:A	C337S	0.986
16:71634607:G:C	C337S	0.986
16:71634382:T:C	F262S	0.984
16:71634337:T:C	F247S	0.983
16:71634652:T:G	F352C	0.983
16:71634426:A:C	S277R	0.982
16:71634428:T:A	S277R	0.982
16:71634428:T:G	S277R	0.982
16:71634627:T:G	Y344D	0.982
16:71634372:G:T	D259Y	0.981
16:71634374:T:A	D259E	0.981
16:71634374:T:G	D259E	0.981
16:71634382:T:G	F262C	0.981
16:71634607:G:A	C337Y	0.981
16:71634361:C:A	A255D	0.980
16:71634616:G:C	R340T	0.980
16:71634395:G:C	K266N	0.979
16:71634395:G:T	K266N	0.979
16:71634243:A:C	S216R	0.978

dbSNP variants (sampled 300 via entrez): RS1000264190 (16:71628985 A>C), RS1000632426 (16:71633124 A>G), RS1000761183 (16:71629354 T>C), RS1000830920 (16:71639682 A>C,G,T), RS1000848139 (16:71624857 C>A), RS1000878825 (16:71628015 G>C), RS1001179834 (16:71639957 C>T), RS1001460172 (16:71636423 G>A), RS1001847719 (16:71636845 C>T), RS1001866218 (16:71641306 C>T), RS1001920620 (16:71631996 A>C), RS1001932592 (16:71629819 G>A,C), RS1002036028 (16:71635172 CA>C,CAA), RS1002289305 (16:71626550 G>A,C), RS1002349257 (16:71631767 T>C)

Disease associations

OMIM: gene MIM:614094 | disease phenotypes: MIM:300755

GenCC curated gene-disease

Mondo (1): immunodeficiency disease (MONDO:0021094)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST001637_4	Malaria	2.000000e-06
GCST003262_260	Post bronchodilator FEV1	3.000000e-06
GCST007269_158	Pulse pressure	2.000000e-18
GCST007565_35	Morning person	1.000000e-15
GCST007576_405	Chronotype	1.000000e-15
GCST008058_208	Estimated glomerular filtration rate	7.000000e-13
GCST008059_185	Estimated glomerular filtration rate	2.000000e-12
GCST010002_114	Refractive error	4.000000e-10
GCST010245_107	LDL cholesterol levels	1.000000e-14

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004314	forced expiratory volume
EFO:0005763	pulse pressure measurement
EFO:0008328	chronotype measurement
EFO:0004611	low density lipoprotein cholesterol measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, decreases expression, increases methylation, affects cotreatment, increases expression	5
sodium arsenite	decreases expression, increases abundance, increases expression, increases methylation	4
Arsenic	affects methylation, increases abundance, increases expression	3
mercuric bromide	increases expression, affects cotreatment	2
entinostat	increases expression, affects cotreatment	2
Benzo(a)pyrene	decreases expression, decreases methylation	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, increases expression	2
sodium arsenate	increases abundance, increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
trichostatin A	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
perfluorooctanoic acid	increases expression	1
manganese chloride	increases abundance, increases expression	1
ochratoxin A	decreases expression	1
perfluorooctane sulfonic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
nutlin 3	affects cotreatment, increases expression	1
dorsomorphin	affects cotreatment, increases expression	1
Resveratrol	decreases expression, affects cotreatment	1
Leflunomide	decreases expression	1
Acetaminophen	decreases expression	1
Camptothecin	increases expression	1
Carbamazepine	affects expression	1
Cisplatin	increases expression	1
Dactinomycin	affects cotreatment, increases expression	1
Diethylhexyl Phthalate	increases expression	1
Manganese	increases abundance, increases expression	1
Plant Extracts	decreases expression, affects cotreatment	1
Silicon Dioxide	decreases expression	1

Clinical trials (associated diseases)

247 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00001542	PHASE4	COMPLETED	Fluconazole Prophylaxis of Thrush in AIDS
NCT00144157	PHASE4	COMPLETED	Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV
NCT00162643	PHASE4	UNKNOWN	PI Vs. NNRTI Based Therapy for HIV Advanced Disease
NCT00273988	PHASE4	COMPLETED	Pharmacokinetic Study of Interaction Between Nevirapine and Methadone in HIV-1 Infected, Opioid-dependent Adults
NCT00981318	PHASE4	TERMINATED	Pilot Assessment of Lopinavir/Ritonavir and Maraviroc
NCT01086878	PHASE4	COMPLETED	Safety of Cotrimoxazole in HIV- and HAART-exposed Infants
NCT01090102	PHASE4	COMPLETED	Mesalamine to Reduce T Cell Activation in HIV Infection
NCT01147042	PHASE4	TERMINATED	Biochemical Response to Interferon-Gamma in Subjects With Specific Gene Mutation in Chronic Granulomatous Disease
NCT01230580	PHASE4	UNKNOWN	Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT)
NCT01465958	PHASE4	COMPLETED	Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency
NCT02274662	PHASE4	COMPLETED	Expanded Access Protocol Thymus Transplantation
NCT02348177	PHASE4	COMPLETED	Pharmacokinetics of Lopinavir/Ritonavir Superboosting in Infants and Young Children Co-infected With HIV and TB
NCT02396979	PHASE4	COMPLETED	Intervention of HIV, Drug Use and the Criminal Justice System in Malaysia
NCT02490956	PHASE4	UNKNOWN	Diagnostic Immunization With Rabies Vaccine in Patients With PID
NCT02503293	PHASE4	COMPLETED	A Study to Compare Quality of Life and Satisfaction in Primary Immunodeficient Patients Treated With Subcutaneous Injections of Gammanorm® 165 mg/mL Administered With Two Different Delivery Devices: Injections Using Pump or Rapid Push
NCT02881437	PHASE4	COMPLETED	IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia
NCT03033745	PHASE4	COMPLETED	Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)
NCT03677557	PHASE4	UNKNOWN	Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment
NCT04192487	PHASE4	COMPLETED	Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in HIV+ Patients With Non-Infectious Diarrhea
NCT04566692	PHASE4	COMPLETED	A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency
NCT05493969	PHASE4	NOT_YET_RECRUITING	Efficacy and Tolerability of DTG Plus 3TC in HIV Infected Adults With Virologically Suppression and TDF Toxicity
NCT06576024	PHASE4	COMPLETED	Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in HIV-infected People
NCT06634641	PHASE4	RECRUITING	Clozapine-related Immunodeficiency in Parkinsons Disease
NCT07076446	PHASE4	ACTIVE_NOT_RECRUITING	An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)
NCT00000118	PHASE3	COMPLETED	Ganciclovir Implant Study for Cytomegalovirus Retinitis
NCT00000134	PHASE3	COMPLETED	Studies of the Ocular Complications of AIDS (SOCA)–Cytomegalovirus Retinitis Retreatment Trial (CRRT)
NCT00000590	PHASE3	COMPLETED	Anti-HIV Immunoglobulin (HIVIG) in Prevention of Maternal-Fetal HIV Transmission (Pediatric ACTG Protocol 185)
NCT00001267	PHASE3	COMPLETED	A Randomized Pilot Study for the Treatment of AIDS or AIDS Related Complex With an Alternating or Simultaneous Combination Regimen of AZT and 2’,3’-Dideoxyinosine
NCT00001646	PHASE3	COMPLETED	Voriconazole vs. Amphotericin B in the Treatment of Invasive Aspergillosis
NCT00144183	PHASE3	COMPLETED	A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS)
NCT00243568	PHASE3	WITHDRAWN	Vicriviroc, a CCR5 Inhibitor, Added to an Optimized Antiretroviral Therapy for Previously Treated HIV (VICTOR-E2) (Study P04285
NCT00278954	PHASE3	COMPLETED	Efficacy, Safety and Pharmacokinetics of Gammaplex in Primary Immunodeficiency Diseases.
NCT00474370	PHASE3	COMPLETED	Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)
NCT00478231	PHASE3	COMPLETED	Multicenter, Safety Study Of Maraviroc
NCT00523211	PHASE3	COMPLETED	Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)
NCT00698334	PHASE3	COMPLETED	Efficacy of Thrice Weekly Directly Observed Treatment, Short-course (DOTS) in HIV-associated Tuberculosis
NCT00966160	PHASE3	COMPLETED	CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes
NCT01363011	PHASE3	COMPLETED	Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal Impairment
NCT01440569	PHASE3	COMPLETED	Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
NCT01475838	PHASE3	COMPLETED	Study to Evaluate Switching From Regimens Consisting of a Ritonavir-boosted Protease Inhibitor Plus Emtricitabine/Tenofovir Fixed-Dose Combination to the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF Single-Tablet Regimen in Virologically Suppressed, HIV-1 Infected Patients